FDA approves rhBMP-2 for orthopedic trauma patients

Infuse bone graft reduced the need for secondary procedures by 44%.

MEMPHIS, Tenn. – Medtronic Inc. announced that the Food and Drug Administration has approved the use of Infuse Bone Graft in the treatment of acute, open fractures of the tibial shaft. The approval broadens the indications for Infuse Bone Graft, a product that has been used since 2002 in spinal surgery with metallic cages.

Approval of Infuse Bone Graft was based on data from a multicenter, prospective, randomized, clinical study of 450 patients. The study, published in the Journal of Bone and Joint Surgery, found that the addition of Infuse Bone Graft improved healing in acute, open fractures of the tibial shaft when compared to standard treatment alone. Infuse Bone Graft also reduced the need for secondary procedures by 44%.

Improves healing

“Because of the associated muscle damage and potential for infection, this type of fracture is difficult to heal,” said Mark Swiontkowski, MD, orthopedic surgeon and past president of the Orthopaedic Trauma Association. “Infuse Bone Graft improves the chances of healing open tibial fractures without the surgeon having to reoperate.”

The approval broadens the indications for Infuse Bone Graft, a product that has been used since 2002 in spinal surgery with metallic cages.

Open fractures of the tibia present a serious orthopedic challenge because fracture healing often occurs slowly or not at all. Nearly 62% of all nonunions occur in the tibia, according to previous research. Consequently, open tibia fractures frequently require additional operations to achieve bone healing, which often impedes a patient’s ability to return to work or normal activity. After severe open fractures, only 28% of patients return to their original work, according to data from the Bone and Joint Decade.

“Infuse Bone Graft could rapidly become the standard of care in open tibia fractures,” said Alan Jones, MD, associate professor and vice chairman in the department of orthopaedic surgery at the University of Texas Southwestern Medical Center at Dallas. “Infuse Bone Graft enhances healing and seems to have a profound, independent effect on the need for secondary intervention after a fracture.”

Infuse Bone Graft contains recombinant human bone morphogenetic protein (rhBMP-2), the genetically engineered version of a naturally occurring protein that is capable of inducing bone growth at the site of implantation. To use Infuse Bone Graft, surgeons reconstitute rhBMP-2 powder with sterile water and apply it to a collagen sponge that is placed over the fracture site after appropriate wound management and fracture stabilization with an intramedullary nail.

MEMPHIS, Tenn. – Medtronic Inc. announced that the Food and Drug Administration has approved the use of Infuse Bone Graft in the treatment of acute, open fractures of the tibial shaft. The approval broadens the indications for Infuse Bone Graft, a product that has been used since 2002 in spinal surgery with metallic cages.

Approval of Infuse Bone Graft was based on data from a multicenter, prospective, randomized, clinical study of 450 patients. The study, published in the Journal of Bone and Joint Surgery, found that the addition of Infuse Bone Graft improved healing in acute, open fractures of the tibial shaft when compared to standard treatment alone. Infuse Bone Graft also reduced the need for secondary procedures by 44%.

Improves healing

“Because of the associated muscle damage and potential for infection, this type of fracture is difficult to heal,” said Mark Swiontkowski, MD, orthopedic surgeon and past president of the Orthopaedic Trauma Association. “Infuse Bone Graft improves the chances of healing open tibial fractures without the surgeon having to reoperate.”

The approval broadens the indications for Infuse Bone Graft, a product that has been used since 2002 in spinal surgery with metallic cages.

Open fractures of the tibia present a serious orthopedic challenge because fracture healing often occurs slowly or not at all. Nearly 62% of all nonunions occur in the tibia, according to previous research. Consequently, open tibia fractures frequently require additional operations to achieve bone healing, which often impedes a patient’s ability to return to work or normal activity. After severe open fractures, only 28% of patients return to their original work, according to data from the Bone and Joint Decade.

“Infuse Bone Graft could rapidly become the standard of care in open tibia fractures,” said Alan Jones, MD, associate professor and vice chairman in the department of orthopaedic surgery at the University of Texas Southwestern Medical Center at Dallas. “Infuse Bone Graft enhances healing and seems to have a profound, independent effect on the need for secondary intervention after a fracture.”

Infuse Bone Graft contains recombinant human bone morphogenetic protein (rhBMP-2), the genetically engineered version of a naturally occurring protein that is capable of inducing bone growth at the site of implantation. To use Infuse Bone Graft, surgeons reconstitute rhBMP-2 powder with sterile water and apply it to a collagen sponge that is placed over the fracture site after appropriate wound management and fracture stabilization with an intramedullary nail.